Company news

Neurizon Therapeutics Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

ONJCRI Evaluates Monepantel Anti-Cancer Mechanism

September 29, 2020

PAA Evaluate MPL Suitability for Ex-Vivo Human COVID-19 Test

September 23, 2020

PAA awarded grant for Phase I trial in Motor Neurone Disease

September 20, 2020

PharmAust Shareholder Update

September 13, 2020

Monepantel Anti-viral Activity Against SARS-CoV-2 Confirmed

September 8, 2020

Elanco Option Update

September 8, 2020

Epichem in partnership to develop waste into fuel technology

August 31, 2020

Appendix 4E & Preliminary Final Report

August 30, 2020

Inhibition of SARS-CoV-2 by MPL in Human Respiratory Cells

August 24, 2020

Reinstatement to Official Quotation

June 17, 2020

Confirmation of Preliminary COVID-19 Results

June 17, 2020

Voluntary Suspension

June 14, 2020

Virtual Investor Briefing Presentation

June 9, 2020

Preliminary Positive Results for the Treatment of SARS-CoV-2

June 3, 2020

Suspension from Official Quotation

June 2, 2020

Monepantel Trial Achieves Successful Anti-Cancer Outcome

May 11, 2020

PharmAust to Evaluate Monepantel on COVID-19

April 16, 2020

Brisbane Animal Hospital Joins Phase II Dog Cancer Trial

March 2, 2020

PharmAust Receives $700k R&D Tax Incentive Refund

January 14, 2020

Epichem Awarded One-Year Contract Extension from DNDi

January 7, 2020

Epichem client gives notice to end contract in February 2020

January 6, 2020

Expanded Site Recruitment for Phase II MPL Dog Cancer Trial

December 11, 2019

Presentation - Pitt Street Research Life Sciences Conference

November 27, 2019

Progress in Recruitment for Phase II Trial in Dogs

November 3, 2019

AGM Presentation

October 25, 2019

Epichem new CEO and Board additions

October 14, 2019

Appendix 3B & s708 Notice

October 10, 2019

PharmAust Receives Pre-Approval for R&D Tax Rebates

October 6, 2019

Epichem Export Business Receives Important WA State Awards

October 3, 2019

PharmAust Raises $2.4m in Placement

October 2, 2019

Agreement with Uni of Melbourne U-Vet for Phase II Dog Trial

September 9, 2019

Phase II Dog Cancer Trial Commences

September 8, 2019

Investor Roadshow Presentation - September 2019

September 8, 2019

Preliminary Final Report

August 30, 2019

Receipt of GMP Grade Tablets for Phase II Trials

August 25, 2019

Response to ASX Price and Volume Query

July 23, 2019

PharmAust receives ethics approval to begin Phase II Trial

July 14, 2019

Epichem Final Loan Repayment Milestone for New Laboratory

July 1, 2019

PharmAust Commences GMP Tablet Manufacture for Phase 2 Trial

June 3, 2019

Receipt of 25kg of GMP-Grade Monepantel from Elanco

May 8, 2019

Phase I Canine Repeat Dose MPL Demonstrates High Performance

May 5, 2019

PharmAust Receives $672,250 R&D Tax Incentive Refund

April 29, 2019

Shortfall Placement Oversubscribed

April 11, 2019

Phase I Monepantel Tablets Demonstrate High Safety

March 27, 2019

PharmAust Raises $1.3m in Rights Issue

March 21, 2019

MPL Tablets Demonstrate Positive Performance in Phase 1

March 13, 2019

PharmAust Rights Issue Reaches Minimum Subscription

March 12, 2019

Appendix 4D & Financial Report

February 28, 2019

Offer Document - Rights Issue

February 25, 2019

Phase I Dog Trial with New Monepantel Tablets Commences

February 19, 2019

← Newer news releases · Older news releases →

Decks

The 5 newest of 36 decks. Every deck is listed under its year.